<DOC>
	<DOCNO>NCT01421368</DOCNO>
	<brief_summary>The purpose study examine effect two contraceptive method menstrual cycle pharmacokinetics , pharmacodynamics tenofovir 1 % gel effect contraceptive method marker mucosal safety .</brief_summary>
	<brief_title>Contraception Menstrual Cycle Effect Pharmacokinetics , Pharmacodynamics Safety Tenofovir Vaginal Gel Use</brief_title>
	<detailed_description>Each woman see 6 visit contact two scheduled follow-up telephone calls/visits . Volunteers consent Visit 1 undergo procedure assess whether eligible continue study . At Visit 2 ( cycle day 20-25 ) , confirm participant meet inclusion criterion none exclusion criterion , genital sample take give 2 applicator tenofovir 1 % gel insert two hour apart . She instruct return Visit 3 , approximately 3 11 hour insertion second gel , determine randomization . The participant retain sample assignment throughout study . At Visit 3 ( cycle day 20-25 ) , blood genital sample collect . The participant give 2 applicator tenofovir 1 % gel insert two hour apart . She instruct return approximately 3 11 hour insertion second gel Visit 4 ( cycle day 5-10 ) blood genital sample take . The participant start contraceptive method choose two method evaluate study . Each participant contact 4-5 week Visit 4 confirm next visit date ( Visit 5 ) . Visit 5 take place 6 week start contraception associate gel use . Follow-up genital sample collect Visit 5 . The participant give 2 applicator tenofovir 1 % gel insert two hour apart prior Visit 6 . Visit 6 take place 10 week start contraception . Follow-up blood genital sample collect approximately 3 11 hour insertion second gel . Each participant also follow-up call visit approximately 1-2 week Visit 6 confirm adverse experience . If necessary , may see unscheduled visit follow-up . She exit study .</detailed_description>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Willing able use OCs DMPA General good health ( volunteer history investigator assessment ) without clinically significant systemic disease Currently regular menstrual cycle 25 35 day volunteer report History Pap smear followup consistent American Congress Obstetricians Gynecologists ( ACOG ) practice bulletin # 99 # 109 willing undergo Pap smear Visit 1 Willing follow protocol requirement include abstinence , use study condom , prohibit use intravaginal product Willing follow postbiopsy restriction least 5 day follow genital biopsy Meets one follow criterion : 1 . Sexually abstinent plan remain abstinent duration study . 2 . In mutually monogamous relationship least last 4 month male partner least 18 year age , willing use condom , know HIV infection risk sexually transmit infection ( STIs ) 3 . In mutually monogamous samesex relationship least last 4 month partner least 18 year age know HIV infection risk STIs Vaginal cervical anatomy , opinion investigator , lend easy genital tract sample collection Negative urine pregnancy test Willing give voluntary consent , sign inform consent form comply study procedure , require protocol History hysterectomy Currently pregnant within 2 calendar month last pregnancy outcome . ( Note : If recently pregnant must least 2 spontaneous menses since pregnancy outcome . ) Use hormonal contraceptive method last 30 day ( oral , transdermal , transvaginal , implant , hormonal intrauterine contraceptive device ) Injection DMPA last 6 month Protection pregnancy presence copper IUD Currently breastfeed breastfed infant last 2 month , plan breastfeed course study History sensitivity/allergy component study product , topical anesthetic , allergy silver nitrate Monsel 's solution Diagnosed treat STI pelvic inflammatory disease last 6 month . ( Note : Women history genital herpes condylomata asymptomatic least 6 month may consider eligibility . ) Positive test Trichomonas vaginalis , Neisseria gonorrhoeae Chlamydia trachomatis Symptomatic vulvovaginal candidiasis , Nugent score great equal 7 screen bacterial vaginosis ( BV ) Visit 2 , urinary tract infection ( UTI ) Deep epithelial genital finding abrasion , ulceration , laceration , vesicle suspicious STIs Positive test HIV Positive test Hepatitis B surface antigen ( HBsAg ) Known bleed disorder could lead prolonged continuous bleed biopsy Chronic acute vulvar vaginal symptom ( e.g. , pain , irritation , spot ) Contraindications choose contraceptive method Known current drug alcohol abuse could impact study compliance Grade 1 high laboratory abnormality , per August 2009 update DAIDS Table Grading Severity Adverse Events Participation investigational trial ( device , drug , vaginal trial ) last 30 day plan participation investigational trial study History gynecological procedure ( include genital piercing ) external genitalia , vagina cervix last 14 day Abnormal find laboratory physical examination social medical condition , opinion investigator , would make participation study unsafe would complicate interpretation data Systemic use last two week anticipate use study follow : corticosteroid , antibiotic , antifungal , antiviral antiretrovirals</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>